Literature DB >> 22318331

Concerning the final report "Hyperthermia: a systematic review" of the Ludwig Boltzmann Institute for Health Technology Assessment, Vienna, March 2010.

R Sauer, H Creeze, M Hulshof, R Issels, O Ott.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22318331     DOI： 10.1007/s00066-012-0072-9

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  19 in total

1.  15-year survival rates after transurethral resection and radiochemotherapy or radiation in bladder cancer treatment.

Authors:  Frens Steffen Krause; Bernhard Walter; Oliver Josef Ott; Lothar Häberle; Christian Weiss; Claus Rödel; Bernd Wullich; Rolf Sauer
Journal:  Anticancer Res       Date:  2011-03       Impact factor: 2.480

2.  Hyperthermia with radiation in the treatment of locally advanced head and neck cancer: a report of randomized trial.

Authors:  Nagraj G Huilgol; Sapna Gupta; C R Sridhar
Journal:  J Cancer Res Ther       Date:  2010 Oct-Dec       Impact factor: 1.805

3.  A randomized clinical trial of radiation therapy versus thermoradiotherapy in stage IIIB cervical carcinoma.

Authors:  Y Harima; K Nagata; K Harima; V V Ostapenko; Y Tanaka; S Sawada
Journal:  Int J Hyperthermia       Date:  2001 Mar-Apr       Impact factor: 3.914

4.  Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group.

Authors:  J van der Zee; D González González; G C van Rhoon; J D van Dijk; W L van Putten; A A Hart
Journal:  Lancet       Date:  2000-04-01       Impact factor: 79.321

Review 5.  Point: Hyperthermia with radiation for chest wall recurrences.

Authors:  Ellen L Jones; Lawrence B Marks; Leonard R Prosnitz
Journal:  J Natl Compr Canc Netw       Date:  2007-03       Impact factor: 11.908

6.  Regional hyperthermia combined with radiotherapy for uterine cervical cancers: a multi-institutional prospective randomized trial of the international atomic energy agency.

Authors:  Arumugam Vasanthan; Michihide Mitsumori; Jeong Ho Park; Zeng Zhi-Fan; Zhong Yu-Bin; Praskovya Oliynychenko; Hideo Tatsuzaki; Yoshiaki Tanaka; Masahiro Hiraoka
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-01-01       Impact factor: 7.038

7.  Quadrimodal treatment of high-risk T1 and T2 bladder cancer: transurethral tumor resection followed by concurrent radiochemotherapy and regional deep hyperthermia.

Authors:  Michael Wittlinger; Claus M Rödel; Christian Weiss; Steffen F Krause; Reinhard Kühn; Rainer Fietkau; Rolf Sauer; Oliver J Ott
Journal:  Radiother Oncol       Date:  2009-11       Impact factor: 6.280

8.  Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results.

Authors:  Claus Rödel; Gerhard G Grabenbauer; Reinhard Kühn; Thomas Papadopoulos; Jürgen Dunst; Martin Meyer; Karl M Schrott; Rolf Sauer
Journal:  J Clin Oncol       Date:  2002-07-15       Impact factor: 44.544

9.  Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic Oncology.

Authors:  J Overgaard; D Gonzalez Gonzalez; M C Hulshof; G Arcangeli; O Dahl; O Mella; S M Bentzen
Journal:  Lancet       Date:  1995-03-04       Impact factor: 79.321

Review 10.  Combined use of hyperthermia and radiation therapy for treating locally advanced cervix carcinoma.

Authors:  Ludy Lutgens; Jacoba van der Zee; Madelon Pijls-Johannesma; Danielle Fm De Haas-Kock; Jeroen Buijsen; Ghislaine Apg van Mastrigt; Guido Lammering; Dirk K M De Ruysscher; Philippe Lambin
Journal:  Cochrane Database Syst Rev       Date:  2010-03-17
View more
  9 in total

1.  Should hyperthermia be included in the benefit catalogue for oncologic indications? Commercial interests are presumed behind the editorial of R. Sauer et al.

Authors:  C Wild
Journal:  Strahlenther Onkol       Date:  2013-01       Impact factor: 3.621

2.  [A century of development in radiation biology. Basic principles of targeted and efficient radiotherapy].

Authors:  C Streffer; T Herrmannn
Journal:  Strahlenther Onkol       Date:  2012-11       Impact factor: 3.621

3.  Effect of a combined surgery, re-irradiation and hyperthermia therapy on local control rate in radio-induced angiosarcoma of the chest wall.

Authors:  M Linthorst; A N van Geel; E A Baartman; S B Oei; W Ghidey; G C van Rhoon; J van der Zee
Journal:  Strahlenther Onkol       Date:  2013-04-04       Impact factor: 3.621

4.  Benefit of replacing the Sigma-60 by the Sigma-Eye applicator. A Monte Carlo-based uncertainty analysis.

Authors:  R A M Canters; M M Paulides; M Franckena; J W Mens; G C van Rhoon
Journal:  Strahlenther Onkol       Date:  2012-11-18       Impact factor: 3.621

5.  Definitive radiotherapy with concurrent oncothermia for stage IIIB non-small-cell lung cancer: A case report.

Authors:  Seung-Gu Yeo
Journal:  Exp Ther Med       Date:  2015-06-11       Impact factor: 2.447

6.  Supportive therapy and complementary medicine in renal cell carcinoma.

Authors:  M Johannsen; C Stoll; M Raida; B van Oorschot; A Flörcken
Journal:  World J Urol       Date:  2021-11-25       Impact factor: 3.661

7.  Modulated electro-hyperthermia in stage III and IV pancreatic cancer: Results of an observational study on 158 patients.

Authors:  Giammaria Fiorentini; Donatella Sarti; Girolamo Ranieri; Cosmo Damiano Gadaleta; Caterina Fiorentini; Carlo Milandri; Andrea Mambrini; Stefano Guadagni
Journal:  World J Clin Oncol       Date:  2021-11-24

8.  Present Practice of Radiative Deep Hyperthermia in Combination with Radiotherapy in Switzerland.

Authors:  Emanuel Stutz; Emsad Puric; Adela Ademaj; Arnaud Künzi; Reinhardt Krcek; Olaf Timm; Dietmar Marder; Markus Notter; Susanne Rogers; Stephan Bodis; Oliver Riesterer
Journal:  Cancers (Basel)       Date:  2022-02-24       Impact factor: 6.639

9.  A Narrative Review of Regional Hyperthermia: Updates From 2010 to 2019.

Authors:  Giammaria Fiorentini; Donatella Sarti; Cosmo Damiano Gadaleta; Marco Ballerini; Caterina Fiorentini; Tommaso Garfagno; Girolamo Ranieri; Stefano Guadagni
Journal:  Integr Cancer Ther       Date:  2020 Jan-Dec       Impact factor: 3.279
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.